A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: HKI-272|DRUG: trastuzumab
Sponsor: Puma Biotechnology, Inc.